Literature DB >> 15019033

Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries.

Kelly M Jenkins1, Reginald Angeles, Marianne T Quintos, Rongda Xu, Daniel B Kassel, Robyn A Rourick.   

Abstract

Early determinations of pharmaceutical properties can serve as predictors of a compound's likely development success. Our laboratory has implemented high throughput in vitro absorption, distribution, metabolism and excretion (ADME) assays which address absorption, metabolism, and physico-chemical properties in an effort to identify potential development liabilities early, thereby minimizing discovery to market attrition. In response to the throughput demands of parallel synthesis, we have incorporated a SAGIAN core robotics system for the determination of both metabolic stability in human liver microsomes (HLMs) and cytochrome P450 (CYP450) inhibition. This automated solution has led to an increase in capacity, throughput and reliability for both in vitro assays. The SAGIAN core robotics system integrates devices such as liquid handlers, plate hotels and incubators through the use of an ORCA robotic arm. The HLM stability assay utilizes a Multimek 96-channel pipettor for liquid handling. The incubation plates are transferred off-line for final semi-quantitative analysis using high throughput parallel LC/MS. The CYP inhibition method combines both liquid handlers and an integrated fluorescence plate reader to perform single concentration percent inhibition assays for 88 compounds. Cytochrome P450 inhibition is measured for both CYP3A4 and CYP2D6 isozymes. This system represents a fully integrated approach to high throughput ADME evaluation in support of drug discovery. The core system concept creates a plug-and-play approach, which combines a series of modular stations to build a robotic platform, which is flexible, upgradable, and easily reconfigured when assays change or are newly developed. The application of these strategies as a means of assessing metabolic stability and CYP inhibition of synthetic libraries is discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15019033     DOI: 10.1016/j.jpba.2003.08.001

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  8 in total

1.  A support vector machine approach to classify human cytochrome P450 3A4 inhibitors.

Authors:  Jan M Kriegl; Thomas Arnhold; Bernd Beck; Thomas Fox
Journal:  J Comput Aided Mol Des       Date:  2005-03       Impact factor: 3.686

2.  Inhibition of protein-protein interactions with low molecular weight compounds.

Authors:  Marilyn M Matthews; David J Weber; Paul S Shapiro; Andrew Coop; Alexander D Mackerell
Journal:  Curr Trends Med Chem       Date:  2008-01-01

Review 3.  Predicting drug metabolism: experiment and/or computation?

Authors:  Johannes Kirchmair; Andreas H Göller; Dieter Lang; Jens Kunze; Bernard Testa; Ian D Wilson; Robert C Glen; Gisbert Schneider
Journal:  Nat Rev Drug Discov       Date:  2015-04-24       Impact factor: 84.694

4.  Strategic use of plasma and microsome binding to exploit in vitro clearance in early drug discovery.

Authors:  George Chang; Stefanus J Steyn; John P Umland; Dennis O Scott
Journal:  ACS Med Chem Lett       Date:  2010-02-03       Impact factor: 4.345

5.  Rapid LC-MS drug metabolite profiling using microsomal enzyme bioreactors in a parallel processing format.

Authors:  Besnik Bajrami; Linlin Zhao; John B Schenkman; James F Rusling
Journal:  Anal Chem       Date:  2009-12-15       Impact factor: 6.986

6.  Advancing microarray assembly with acoustic dispensing technology.

Authors:  E Y Wong; S L Diamond
Journal:  Anal Chem       Date:  2009-01-01       Impact factor: 6.986

Review 7.  Current status and future directions of high-throughput ADME screening in drug discovery.

Authors:  Wilson Z Shou
Journal:  J Pharm Anal       Date:  2020-05-23

8.  Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034.

Authors:  K-C Cheng; Walter A Korfmacher; Ronald E White; F George Njoroge
Journal:  Perspect Medicin Chem       Date:  2007-06-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.